MCID: DYS014
MIFTS: 50

Dyspepsia

Categories: Gastrointestinal diseases

Aliases & Classifications for Dyspepsia

MalaCards integrated aliases for Dyspepsia:

Name: Dyspepsia 12 42 14
Indigestion 12 41
Dyspepsia, Indigestion Nos 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2321
ICD10 33 K30 R10.13
MeSH 42 D004415
NCIt 47 C26756
UMLS 69 C0013395

Summaries for Dyspepsia

MedlinePlus : 41 nearly everyone has had indigestion at one time. it's a feeling of discomfort or a burning feeling in your upper abdomen. you may have heartburn or belch and feel bloated. you may also feel nauseated, or even throw up. you might get indigestion from eating too much or too fast, eating high-fat foods, or eating when you're stressed. smoking, drinking too much alcohol, using some medicines, being tired, and having ongoing stress can also cause indigestion or make it worse. sometimes the cause is a problem with the digestive tract, like an ulcer or gerd. avoiding foods and situations that seem to cause it may help. because indigestion can be a sign of a more serious problem, see your health care provider if it lasts for more than two weeks or if you have severe pain or other symptoms. your health care provider may use x-rays, lab tests, and an upper endoscopy to diagnose the cause. you may need medicines to treat the symptoms. nih: national institute of diabetes and digestive and kidney diseases

MalaCards based summary : Dyspepsia, also known as indigestion, is related to eosinophilic gastroenteritis and schizophrenia. An important gene associated with Dyspepsia is TRPV1 (Transient Receptor Potential Cation Channel Subfamily V Member 1), and among its related pathways/superpathways are Peptide ligand-binding receptors and Neuroscience. The drugs Aspirin and Esomeprazole have been mentioned in the context of this disorder. Affiliated tissues include testes, kidney and brain, and related phenotypes are Decreased viability and behavior/neurological

Wikipedia : 72 Indigestion, also known as dyspepsia, is a condition of impaired digestion. Symptoms may include upper... more...

Related Diseases for Dyspepsia

Diseases related to Dyspepsia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 140)
id Related Disease Score Top Affiliating Genes
1 eosinophilic gastroenteritis 28.2 CXCL8 GHRL HRH2 PGC PTGS2
2 schizophrenia 27.5 CCK CCKAR GNB3 HRH2 HTR1A HTR3A
3 stomach cancer 10.9
4 opisthorchiasis 10.8
5 taeniasis 10.7
6 bacterial gastritis 10.7
7 prinzmetal's variant angina 10.7
8 diabetic neuropathy 10.7
9 stomach disease 10.7
10 viral gastritis 10.7
11 nutritional optic neuropathy 10.5 GHRL SST
12 cushing's syndrome 10.5 CCK PTGS2
13 ischemic neuropathy 10.5 CCK GHRL HTR3A
14 ornithosis 10.5 CCK HTR3A SLC6A4
15 perinatal necrotizing enterocolitis 10.5 CCK GHRL SLC6A4
16 chronic tympanitis 10.5 CCK TRPV1
17 chromosome 11p13 deletion syndrome, distal 10.5 CCK GHRL SLC6A4
18 perianal hematoma 10.5 CCK SST
19 bladder neck cancer 10.4 CYP2C19 HRH2
20 immunodeficiency 27b, mycobacteriosis, ad 10.4 CYP2C19 PTGS2
21 allergic urticaria 10.3 CCK GHRL
22 bile duct cystadenocarcinoma 10.3 CCK SST
23 duodenitis 10.3
24 irritable bowel syndrome 10.3
25 chagas disease 10.3 CCK GHRL HTR3A SLC6A4
26 ovarian remnant syndrome 10.3 PTGS1 PTGS2
27 iris mixed cell melanoma 10.3 CCK HRH2 SST
28 neuroendocrine tumor 10.2 PTGS1 PTGS2
29 neonatal marfan syndrome 10.2 CXCL8 PTGS2
30 dermatomyositis 10.2 CCK CCKAR SST
31 pervasive developmental disorder 10.2 CCK GHRL SLC6A4 TRPV1
32 survival motor neuron spinal muscular atrophy 10.2 GHRL SST TRPV1
33 chondroma 10.2 CCK SST TRPV1
34 typhoid fever 10.2 CCK HTR3A SST
35 abnormal pupillary function 10.1 HTR1A HTR3A
36 gastroparesis 10.1
37 gastroesophageal reflux 10.1
38 brain ependymoma 10.1 HRH2 PTGS1 PTGS2
39 conjunctival degeneration 10.1 HTR1A SLC6A4
40 sweat gland cancer 10.1 CCK HTR3A SLC6A4 SST
41 duodenal ulcer 10.1
42 endometrial clear cell adenocarcinoma 10.0 CXCL8 GHRL TRPV1
43 gastritis 10.0
44 peptic ulcer disease 10.0
45 uterus intravascular leiomyomatosis 10.0 HTR1A SLC6A4
46 mucositis 10.0
47 acrocephalopolydactylous dysplasia 10.0 SLC6A4 TRPV1
48 heart disease 10.0
49 anodontia 10.0 HTR1A HTR3A SLC6A4
50 renpenning syndrome 9.9 HTR1A HTR3A SLC6A4

Graphical network of the top 20 diseases related to Dyspepsia:



Diseases related to Dyspepsia

Symptoms & Phenotypes for Dyspepsia

GenomeRNAi Phenotypes related to Dyspepsia according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00381-A-1 9.23 HTR1A HTR3A SLC6A4 HRH2
2 Decreased viability GR00381-A-3 9.23 HRH2 HTR1A HTR3A SLC6A4

MGI Mouse Phenotypes related to Dyspepsia:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.11 CCK CCKAR GHRL HRH2 HTR1A HTR3A
2 homeostasis/metabolism MP:0005376 9.9 CCK CCKAR GHRL HRH2 HTR1A HTR3A
3 endocrine/exocrine gland MP:0005379 9.86 SLC6A4 CCK CCKAR GHRL HRH2 HTR3A
4 digestive/alimentary MP:0005381 9.8 CCKAR GHRL HRH2 PTGS1 PTGS2 SST
5 nervous system MP:0003631 9.7 CCKAR GNB3 HRH2 HTR1A HTR3A PTGS1
6 renal/urinary system MP:0005367 9.02 CCKAR HTR3A PTGS1 PTGS2 TRPV1

Drugs & Therapeutics for Dyspepsia

Drugs for Dyspepsia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 333)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aspirin Approved, Vet_approved Phase 4,Phase 3 50-78-2 2244
2
Esomeprazole Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 161796-78-7, 119141-88-7 4594 9579578
3
Famotidine Approved Phase 4,Phase 3 76824-35-6 3325
4
Histamine Approved, Investigational Phase 4,Phase 2,Phase 3 75614-87-8, 51-45-6 774
5
Mianserin Approved Phase 4 24219-97-4 4184
6
Mirtazapine Approved Phase 4 85650-52-8, 61337-67-5 4205
7
Pantoprazole Approved Phase 4,Phase 2,Phase 3 102625-70-7 4679
8
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Phase 2 26787-78-0 33613 2171
9
Clarithromycin Approved Phase 4,Phase 3,Phase 2 81103-11-9 84029
10
Dexlansoprazole Approved Phase 4,Phase 3,Phase 1,Phase 2 138530-94-6, 103577-45-3 9578005
11
Lansoprazole Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 103577-45-3 3883
12
Celecoxib Approved, Investigational Phase 4,Phase 3 169590-42-5 2662
13
Naproxen Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 22204-53-1 1302 156391
14
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
15 Racepinephrine Approved Phase 4
16
Metronidazole Approved Phase 4,Phase 3 443-48-1 4173
17
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 73590-58-6 4594
18
Amitriptyline Approved Phase 4,Phase 2,Phase 3 50-48-6 2160
19
Cyclobenzaprine Approved Phase 4 303-53-7 2895
20
Ranitidine Approved Phase 4,Phase 2,Phase 3 66357-59-3, 66357-35-5 3001055
21
Dopamine Approved Phase 4,Phase 3,Phase 1 51-61-6, 62-31-7 681
22
Aluminum hydroxide Approved Phase 4,Phase 3 21645-51-2
23
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
24
Potassium Citrate Approved, Vet_approved Phase 4
25
Magnesium Hydroxide Approved Phase 4 1309-42-8
26
Furazolidone Approved, Vet_approved Phase 4 67-45-8 3435 5323714
27
Levofloxacin Approved, Investigational Phase 4,Phase 3 100986-85-4 149096
28
Ofloxacin Approved Phase 4,Phase 3 82419-36-1 4583
29
Azithromycin Approved Phase 4 83905-01-5 55185 53477736 447043
30
Erythromycin Approved, Vet_approved Phase 4 114-07-8 12560
31
Lubiprostone Approved, Investigational Phase 4 136790-76-6 656719
32
Ibuprofen Approved Phase 4,Phase 3 15687-27-1 3672
33
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
34
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
35
Guaifenesin Approved, Vet_approved Phase 4,Phase 3 93-14-1 3516
36
Tinidazole Approved, Investigational Phase 4,Phase 2,Phase 3 19387-91-8 5479
37
Rabeprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 117976-89-3 5029
38
Loperamide Approved Phase 4,Phase 2,Phase 3 53179-11-6 3955
39
Pectin Approved, Vet_approved Phase 4 9000-69-5 441476
40
Trimebutine Approved Phase 4 39133-31-8
41
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
42 Parecoxib Approved Phase 4 198470-84-7
43
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
44
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3 59-30-3 6037
45
leucovorin Approved, Nutraceutical Phase 4,Phase 3 58-05-9 143 6006
46
Ginseng Approved, Nutraceutical Phase 4 50647-08-0
47 Licorice Approved, Nutraceutical Phase 4
48 Mosapride Investigational Phase 4,Phase 3,Phase 1,Phase 2 112885-41-3
49 Rebamipide Investigational Phase 4,Phase 3 90098-04-7
50
Maleic acid Experimental Phase 4 110-16-7 444266

Interventional clinical trials:

(show top 50) (show all 320)

id Name Status NCT ID Phase Drugs
1 Esomeprazole or Famotidine in the Management of Aspirin Related Non-Ulcer Dyspepsia Unknown status NCT00978159 Phase 4 esomeprazole;Famotidine
2 Mirtazapine Versus Placebo in Functional Dyspepsia Unknown status NCT01240096 Phase 4 Mirtazapine
3 The Efficacy of Pantoprazole Treatment in Patients With Functional Dyspepsia Unknown status NCT01608750 Phase 4 Pantoprazol;Folic Acid
4 Clinical Study to Evaluate the Efficacy and the Safety of Eradication Therapy for Helicobacter Pylori in Functional Dyspepsia Unknown status NCT00990405 Phase 4 Lansoprzole+Amoxicillin+Clarithromycin
5 Gastric Functions & Proton Pump Inhibitor( PPI) Study Unknown status NCT00951431 Phase 4 Esomeprazole;Placebo
6 Study of Long-Term Use of Proton-Pump-Inhibitors in General Practice Unknown status NCT00363701 Phase 4 esomeprazole
7 Prucalopride Versus Placebo in Gastroparesis Unknown status NCT02510976 Phase 4 prucalopride;placebo
8 Gastro-protective Effect and Pain Relief Effect of Naxozol Compared to Celecoxib in Patients With Osteoarthritis Unknown status NCT02355236 Phase 4 Naproxen/Esomeprazol 500/20mg;Celecoxib 200mg;Naxozol-Placebo;Comparator-Placebo
9 Efficacy Study of Articaine Lozenge to Enhance the Procedural Compliance of the Adults Undergoing Gastroduodenoscopy Unknown status NCT02105090 Phase 4 Anesthetics, Local;Sodium Chloride 0.9%
10 Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice Unknown status NCT01273441 Phase 4 PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin
11 14-day Quadruple Hybrid vs. Concomitant Therapies for Helicobacter Pylori Eradication Unknown status NCT01464060 Phase 4 PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin
12 Cyclobenzaprine Extended Release (ER) for Fibromyalgia Unknown status NCT01041495 Phase 4 cyclobenzaprine ER (AMRIX);placebo
13 Efficacy of Banhasasim-tang on Functional Dyspepsia Completed NCT00987805 Phase 4
14 Comparison of Pantoprazole and Ranitidine in Dyspepsia Completed NCT01737840 Phase 4 Pantoprazole;Ranitidine
15 The Efficacy and Safety Study of Rikkunshito in Patients With Functional Dyspepsia Completed NCT02037776 Phase 4 Rikkunshito;Rikkunshito placebo
16 Compliance With Antidepressant Medication in Treatment of Functional Dyspepsia Completed NCT01851863 Phase 4 Omeprazole;Flupentixol-Melitracen(psychological and GI) + Omeprazole;Flupentixol-Melitracen(psychological) + Omeprazole;Flupentixol-Melitracen(without explanation) + Omeprazole
17 Lansoprazole Versus Mosapride for Functional Dyspepsia Completed NCT00663897 Phase 4 lansoprazole;mosapride
18 A Study to Demonstrate the Efficacy and Safety of Motilitone® Completed NCT01817465 Phase 4 Motilitone ®;Pantoline®;Motilitone® and Pantoline®
19 The Efficacy and Safety of Qizhiweitong Granule on Patients With Functional Dyspepsia in a Multi-center Clinical Study Completed NCT02460601 Phase 4 Qizhiweitong granule
20 A Comparison of Efficacy of Intravenous Esomeprazole and Ranitidine Treatment of Dyspeptic Pain Completed NCT02197143 Phase 4 esomeprazole;Ranitidine;hydrotalcid
21 High Dose PPI Triple Therapy Versus Sequential Therapy for Helicobacter Pylori Eradication Completed NCT01888237 Phase 4 Double dose of PPI;sequence of drug use
22 Proton Pump Inhibitor Treatment Stop Completed NCT00120315 Phase 4 esomeprazole
23 Bifidobacteria In Children With Abdominal Pain-Associated Functional Gastrointestinal Disorders Completed NCT02566876 Phase 4 Mixture of three Bifidobacteria
24 Amoxicillin/Metronidazole Based Quadruple Therapy for Helicobacter Pylori Eradication Completed NCT02175901 Phase 4 Lansoprazole;Bismuth Potassium Citrate;Amoxicillin;Metronidazole;Clarithromycin
25 Symptomatic Relief of Acute Dyspeptic Pain in Emergency Department With Pantoprazole Completed NCT01281501 Phase 4 Normal saline;Pantoprazole;Oral antacid;Hyoscine butylbromide
26 Empirical Rescue Therapies of Helicobacter Pylori Infection Completed NCT01668927 Phase 4 Proton Pump Inhibitor;Bismuth;Metronidazole;Tetracycline;Furazolidone;Amoxicillin
27 Bismuth Improves the Efficacy of Levofloxacin-containing Triple Therapy for Helicobacter Pylori Treatment Completed NCT01667718 Phase 4 Bismuth;Lansoprazole;Levofloxacin;Amoxicillin
28 Amtolmetin Gaucil in Knee Osteoarthritis Completed NCT02865161 Phase 4 NISELAT
29 Aizthromycin or Clarithromycin in H-pylori Eradication Regimen Completed NCT01667692 Phase 4 azithromycin;clarithmycin
30 Efficiency Study of Clarithromycin and Bismuth-containing Quadruple Therapy to Treat H.Pylori Completed NCT01667575 Phase 4 Esomeprazole;Amoxicillin;Clarithromycin;Bismuth Potassium Citrate
31 Helicobacter Pylori Eradication With Berberine Quadruple Therapy Versus Clarithromycin Quadruple Therapy Completed NCT02633930 Phase 4 Berberine;clarithromycin;Bismuth;Lansoprazole;amoxicillin
32 Helicobacter Pylori Eradication With Berberine Quadruple Therapy Versus Bismuth-containing Quadruple Therapy Completed NCT02296021 Phase 4 Berberine;Bismuth;esomeprazole;amoxicillin;clarithromycin
33 Ulcer Prevention Study in Post Gastric Bypass Patients Completed NCT00557349 Phase 4 Omeprazole;Famotidine
34 Effects of Lubiprostone on Small Bowel and Colonic Bacteria: A Correlation Study With Segmental and Whole Gut Transit Completed NCT00844831 Phase 4 Lubiprostone
35 Efficacy and Safety of Ilaprazole Based Bismuth-containing Quadruple Regimen for the First-line Treatment of Helicobacter Pylori Infection Completed NCT02835560 Phase 4 Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy;Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapy
36 Glucomannan for the Treatment of Abdominal Pain-related Functional Gastrointestinal Disorders in Childhood Completed NCT01495806 Phase 4 Glucomannan;placebo
37 Famotidine Compared With Pantoprazole to Prevent Recurrent Aspirin-Induced Peptic Ulcer/Erosion Completed NCT00843063 Phase 4 pantoprazole vs famotidine
38 Efficacy and Safety of Valdecoxib and Naproxen in Treating the Signs and Symptoms of Rheumatoid Arthritis (RA) in a Severe Rheumatoid Arthritis Patients Completed NCT00650455 Phase 4 valdecoxib;naproxen;placebo
39 Comparison of Small Bowel Lesions Associated With Celecoxib Versus Ibuprofen Plus Omeprazole Completed NCT00640809 Phase 4 Celecoxib;Ibuprofen plus Omeprazole
40 Randomized, Double Blind, Multicenter Study of the Safety and Efficacy of Valdecoxib 40 mg Once Daily Compared With Diclofenac 75 mg Twice Daily in Acute Low Back Pain Completed NCT00649610 Phase 4 valdecoxib;diclofenac
41 Rebamipide in Combination With Esomeprazole in the Management of Asian Patients With Functional Dyspepsia Recruiting NCT02134405 Phase 4 Rebamipide;Placebo (for Esomeprazole);Esomeprazole
42 Clinical Trial of Efficacy and Safety of Kolofort in Functional Dyspepsia Patients Recruiting NCT03119766 Phase 4 Kolofort;Placebo
43 BRAVO Study for Functional Dyspepsia Recruiting NCT01349413 Phase 4 Esomeprazole 20mg
44 Effect of Short-term Motilitone Therapy on Health-related Quality of Life in PD Patients With Gastrointestinal Symptoms Recruiting NCT02775591 Phase 4 DA-9701;DA-9701 placebo
45 Mast Cells in Acid-induced Intestinal Permeability Recruiting NCT02664051 Phase 4 Nalcrom;placebo
46 Antimicrobial Susceptibility Testing Guided Antibiotic Selection Strategies in Salvage Helicobacter Pylori Treatment Recruiting NCT02988089 Phase 4 Clarithromycin susceptibility dependant strategy;2 susceptible antibiotics (amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline );proton pump inhibitor (PPI) and Colloidal Bismuth Pectin;amoxicillin and clarithromycin or amoxicillin and furazolidone;amoxicillin and furazolidone or amoxicillin and tetracycline;amoxicillin and furazolidone or amoxicillin and Tinidazole or amoxicillin and Levofloxacin
47 Heweizhixie capsuleTherapy on Patients With Diarrhea Recruiting NCT02607176 Phase 4 Heweizhixie capsule
48 Helicobacter Eradication Aspirin Trial Recruiting NCT01506986 Phase 4 Lansoprazole 30mg, Clarithromycin 500mg, Metronidazole 400mg;Placebo lansoprazole 30mg, clarithromycin 500mg, metronidazole 400mg
49 Trimebutine Maleate Combined With Rabeprazole in Patients With Grade A or B Reflux Esophagitis Whose Symptoms Refractory to Rabeprazole Recruiting NCT02986685 Phase 4 Trimebutine Maleate;rabeprazole
50 Therapeutic Effect of Ursodeoxycholic Acid in Functional Dyspepsia Not yet recruiting NCT03004118 Phase 4 Placebo Oral Tablet;Ursochol oral tablet

Search NIH Clinical Center for Dyspepsia

Cochrane evidence based reviews: dyspepsia

Genetic Tests for Dyspepsia

Anatomical Context for Dyspepsia

MalaCards organs/tissues related to Dyspepsia:

39
Testes, Kidney, Brain, Small Intestine, Liver, Tongue, Heart

Publications for Dyspepsia

Articles related to Dyspepsia:

(show top 50) (show all 773)
id Title Authors Year
1
Food and functional dyspepsia: a systematic review. ( 28913843 )
2017
2
Acupuncture and related therapies used as add-on or alternative to prokinetics for functional dyspepsia: overview of systematic reviews and network meta-analysis. ( 28871092 )
2017
3
Development of a Symptom-Focused Patient-Reported Outcome Measure for Functional Dyspepsia: The Functional Dyspepsia Symptom Diary (FDSD). ( 28925989 )
2017
4
Minimal differences in prevalence and spectrum of organic disease at upper gastrointestinal endoscopy between selected secondary care patients with symptoms of gastro-oesophageal reflux or dyspepsia. ( 27973922 )
2017
5
A magnetic resonance imaging study of gastric motor function in patients with dyspepsia associated with Ehlers-Danlos Syndrome-Hypermobility Type: A feasibility study. ( 28568908 )
2017
6
Pathophysiological Abnormalities in Functional Dyspepsia Subgroups According to the Rome III Criteria. ( 27958284 )
2017
7
Certain Dietary Habits Contribute to the Functional Dyspepsia in South China Rural Area. ( 28809820 )
2017
8
Celiac disease prevalence is not increased in patients with functional dyspepsia. ( 28079237 )
2017
9
Impaired vagal activity to meal in patients with functional dyspepsia and delayed gastric emptying. ( 28874084 )
2017
10
Is small intestinal bacterial overgrowth involved in the pathogenesis of functional dyspepsia? ( 28818267 )
2017
11
The Role of Duodenal Inflammation in Functional Dyspepsia. ( 27811629 )
2017
12
Superior Mesenteric Artery Syndrome May Be Overlooked in Women with Functional Dyspepsia. ( 28883239 )
2017
13
Modified Helicobacter test using a new test meal and a (13)C-urea breath test in Helicobacter pylori positive and negative dyspepsia patients on proton pump inhibitors. ( 28932087 )
2017
14
Editorial: Moving Away From Focussing on Gastric Pathophysiology in Functional Dyspepsia: New Insights and Therapeutic Implications. ( 28050031 )
2017
15
Effectiveness of Quercus brantii hydroalcoholic extract on dyspepsia: A randomized, double blind clinical trial. ( 28852653 )
2017
16
Efficacy and safety of Xiangsha Liujunzi granules for functional dyspepsia: A multi-center randomized double-blind placebo-controlled clinical study. ( 28852318 )
2017
17
Functional dyspepsia and gastroparesis. ( 28832359 )
2017
18
Definition, Pathogenesis and Management of that cursed Dyspepsia. ( 28899670 )
2017
19
Sini-san improves duodenal tight junction integrity in a rat model of functional dyspepsia. ( 28854971 )
2017
20
"First Do No Harm": Adverse Events from Pharmaceutical Treatment of Gastroparesis and Dyspepsia. ( 28932929 )
2017
21
Weikangning therapy in functional dyspepsia and the protective role of Nrf2. ( 28928800 )
2017
22
How should we manage patients with functional dyspepsia in clinical practice? ( 28884565 )
2017
23
Plasma ghrelin level and plasma ghrelin/obestatin ratio are related to intestinal metaplasia in elderly patients with functional dyspepsia. ( 28419119 )
2017
24
Overlap between irritable bowel syndrome and functional dyspepsia including subtype analyses. ( 28160607 )
2017
25
Effects of Bu-Zhong-Yi-Qi-Tang for the treatment of functional dyspepsia: a feasibility study protocol. ( 28951846 )
2017
26
Exhaled nitric oxide as a potential marker for detecting non-ulcer dyspepsia and peptic ulcer disease. ( 28947681 )
2017
27
Gender Difference of Gastric Emptying in Healthy Volunteers and Patients with Functional Dyspepsia. ( 28052285 )
2017
28
Self-rated health and functional capacity in individuals reporting overlapping symptoms of gastroesophageal reflux disease, functional dyspepsia and irritable bowel syndrome - a population based study. ( 28521729 )
2017
29
Evaluating community pharmacists` dyspepsia knowledge: A cross-sectional study in Tehran, Iran. ( 27594437 )
2016
30
A prospective study on symptom generation according to spicy food intake and TRPV1 genotypes in functional dyspepsia patients. ( 27094759 )
2016
31
Dietary fat intake and functional dyspepsia. ( 27195249 )
2016
32
Sero-prevalence and associated factors of Helicobacter pylori infection among adult patients with dyspepsia attending the gastroenterology unit in a tertiary hospital in Mwanza, Tanzania. ( 27917200 )
2016
33
Profile of acotiamide in the treatment of functional dyspepsia. ( 27103837 )
2016
34
Gastric Activity and Gut Peptides in Patients With Functional Dyspepsia: Postprandial Distress Syndrome Versus Epigastric Pain Syndrome. ( 27092429 )
2016
35
Gastric siderosis as a cause of dyspepsia. ( 27511759 )
2016
36
Epidemiology and risk factors of uninvestigated dyspepsia, irritable bowel syndrome, and gastroesophageal reflux disease among students of Damascus University, Syria. ( 27501053 )
2016
37
An unusual cause of dyspepsia due to a retained epicardial pacing wire. ( 28906227 )
2016
38
Individualized Acupuncture for Symptom Relief in Functional Dyspepsia: A Randomized Controlled Trial. ( 27732083 )
2016
39
Effects of Lactobacillus gasseri OLL2716 on Helicobacter pylori-Associated Dyspepsia: A Multicenter Randomized Double-Blind Controlled Trial. ( 27478434 )
2016
40
Implementation and evaluation of early gastroscopy for patients with dyspepsia and warning signs in Primary Care. ( 28010892 )
2016
41
Validation of the Leuven Postprandial Distress Scale, a questionnaire for symptom assessment in the functional dyspepsia/postprandial distress syndrome. ( 27518319 )
2016
42
Higher Frequency of Reflux Symptoms and Acid-Related Dyspepsia in Women than Men Regardless of Endoscopic Esophagitis: Analysis of 3,505 Japanese Subjects Undergoing Medical Health Checkups. ( 27160990 )
2016
43
Influence of CYP2C19 on Helicobacter pylori eradication in Brazilian patients with functional dyspepsia. ( 27706745 )
2016
44
Decreased Number of Duodenal Endocrine Cells with Unaltered Serotonin-Containing Cells in Functional Dyspepsia. ( 27924095 )
2016
45
Functional dyspepsia susceptibility is related to CD14, GNB3, MIF, and TRPV1 gene polymorphisms in the Greek population. ( 27430937 )
2016
46
Helicobacter pylori eradication effect on patients with functional dyspepsia symptoms. ( 27091036 )
2016
47
Dyspepsia and constipation in patients with schizophrenia spectrum disorders. ( 27564411 )
2016
48
Sleep disturbance due to heartburn and regurgitation is common in patients with functional dyspepsia. ( 27087946 )
2016
49
Functional dyspepsia: new insights into pathogenesis and therapy. ( 27048251 )
2016
50
Helicobacter pylori and Its Virulence Factors' Effect on Serum Oxidative DNA Damages in Adults With Dyspepsia. ( 28033692 )
2016

Variations for Dyspepsia

Expression for Dyspepsia

Search GEO for disease gene expression data for Dyspepsia.

Pathways for Dyspepsia

Pathways related to Dyspepsia according to GeneCards Suite gene sharing:

(show all 12)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.18 CCK CCKAR CXCL8 GHRL GNB3 HRH2
2 12.24 GNB3 HTR1A PTGS1 PTGS2
3
Show member pathways
11.74 GNB3 HTR1A HTR3A
4
Show member pathways
11.7 CYP2C19 PTGS1 PTGS2
5 11.65 CXCL8 GNB3 HTR1A HTR3A SLC6A4 SST
6 11.25 CYP2C19 GNB3 PTGS1
7 11.22 CYP2C19 GNB3 HTR1A HTR3A PTGS1 PTGS2
8 10.94 HTR1A HTR3A SLC6A4
9 10.89 PTGS1 PTGS2
10 10.86 PTGS1 PTGS2
11 10.61 CXCL8 PTGS1 PTGS2
12 10.58 PTGS1 PTGS2

GO Terms for Dyspepsia

Cellular components related to Dyspepsia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 neuronal cell body GO:0043025 9.46 CCK HTR3A SST TRPV1
2 neuron projection GO:0043005 9.26 GNB3 PTGS2 SLC6A4 TRPV1
3 organelle membrane GO:0031090 8.8 CYP2C19 PTGS1 PTGS2

Biological processes related to Dyspepsia according to GeneCards Suite gene sharing:

(show all 18)
id Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.85 CXCL8 PTGS1 PTGS2 TRPV1
2 positive regulation of cytosolic calcium ion concentration GO:0007204 9.73 CCKAR GHRL TRPV1
3 response to nutrient GO:0007584 9.63 CCKAR SLC6A4 SST
4 excitatory postsynaptic potential GO:0060079 9.61 GHRL HTR3A TRPV1
5 regulation of blood pressure GO:0008217 9.58 GNB3 PTGS1 PTGS2
6 decidualization GO:0046697 9.57 GHRL PTGS2
7 prostaglandin metabolic process GO:0006693 9.54 PTGS1 PTGS2
8 digestion GO:0007586 9.54 CCKAR PGC SST
9 vasoconstriction GO:0042310 9.52 HTR1A SLC6A4
10 prostaglandin biosynthetic process GO:0001516 9.51 PTGS1 PTGS2
11 memory GO:0007613 9.5 HRH2 PTGS2 SLC6A4
12 G-protein coupled receptor signaling pathway GO:0007186 9.5 CCKAR CXCL8 GHRL GNB3 HRH2 HTR1A
13 cellular response to ATP GO:0071318 9.49 PTGS2 TRPV1
14 cyclooxygenase pathway GO:0019371 9.48 PTGS1 PTGS2
15 response to organonitrogen compound GO:0010243 9.33 PTGS2 SST TRPV1
16 regulation of hormone secretion GO:0046883 9.26 CCKAR HTR1A
17 negative regulation of synaptic transmission, dopaminergic GO:0032227 8.62 PTGS2 SLC6A4
18 signal transduction GO:0007165 10.05 CCK CCKAR CXCL8 GNB3 HRH2 HTR1A

Molecular functions related to Dyspepsia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 signal transducer activity GO:0004871 9.62 CCKAR GNB3 HRH2 HTR1A
2 heme binding GO:0020037 9.43 CYP2C19 PTGS1 PTGS2
3 peroxidase activity GO:0004601 9.37 PTGS1 PTGS2
4 hormone activity GO:0005179 9.33 CCK GHRL SST
5 serotonin binding GO:0051378 8.96 HTR1A HTR3A
6 prostaglandin-endoperoxide synthase activity GO:0004666 8.62 PTGS1 PTGS2

Sources for Dyspepsia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....